HUE063998T2 - Imidazo[4,5-b]piridin vegyületek és azok gyógyászati készítményei gyulladásos betegségek kezelésére - Google Patents

Imidazo[4,5-b]piridin vegyületek és azok gyógyászati készítményei gyulladásos betegségek kezelésére

Info

Publication number
HUE063998T2
HUE063998T2 HUE18788711A HUE18788711A HUE063998T2 HU E063998 T2 HUE063998 T2 HU E063998T2 HU E18788711 A HUE18788711 A HU E18788711A HU E18788711 A HUE18788711 A HU E18788711A HU E063998 T2 HUE063998 T2 HU E063998T2
Authority
HU
Hungary
Prior art keywords
imidazo
treatment
pharmaceutical compositions
inflammatory disorders
pyridine compounds
Prior art date
Application number
HUE18788711A
Other languages
English (en)
Inventor
Der Plas Steven Van
Oscar Mammoliti
Sebastien Martina
Pieter Claes
Ghjuvanni Coti
Denis Annoot
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of HUE063998T2 publication Critical patent/HUE063998T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
HUE18788711A 2017-10-20 2018-10-11 Imidazo[4,5-b]piridin vegyületek és azok gyógyászati készítményei gyulladásos betegségek kezelésére HUE063998T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1717260.2A GB201717260D0 (en) 2017-10-20 2017-10-20 Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
HUE063998T2 true HUE063998T2 (hu) 2024-02-28

Family

ID=60481889

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18788711A HUE063998T2 (hu) 2017-10-20 2018-10-11 Imidazo[4,5-b]piridin vegyületek és azok gyógyászati készítményei gyulladásos betegségek kezelésére

Country Status (29)

Country Link
US (2) US11564923B2 (hu)
EP (2) EP3697784B9 (hu)
JP (2) JP7292271B2 (hu)
KR (1) KR20200074178A (hu)
CN (2) CN111225916B (hu)
AR (1) AR113784A1 (hu)
AU (2) AU2018350592B2 (hu)
BR (1) BR112020007541A2 (hu)
CA (1) CA3079449A1 (hu)
CO (1) CO2020005200A2 (hu)
DK (1) DK3697784T5 (hu)
ES (1) ES2967432T3 (hu)
FI (1) FI3697784T5 (hu)
GB (1) GB201717260D0 (hu)
HR (1) HRP20231315T1 (hu)
HU (1) HUE063998T2 (hu)
IL (2) IL302615A (hu)
LT (1) LT3697784T (hu)
MA (1) MA50391B1 (hu)
MX (1) MX2020003863A (hu)
PH (1) PH12020550230A1 (hu)
PL (1) PL3697784T3 (hu)
PT (1) PT3697784T (hu)
RS (1) RS64800B1 (hu)
SG (1) SG11202003516TA (hu)
SI (1) SI3697784T1 (hu)
TW (1) TWI805629B (hu)
WO (1) WO2019076716A1 (hu)
ZA (1) ZA202002166B (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
AU2020284742A1 (en) * 2019-05-28 2022-02-03 Mankind Pharma Ltd. Novel compounds for inhibition of Janus Kinase 1
CA3225221A1 (en) 2021-07-12 2023-01-19 Galapagos Nv Treatment of inflammatory diseases
WO2023161327A1 (en) 2022-02-24 2023-08-31 Galapagos Nv Compound for use in and methods of treatment of inflammatory diseases
WO2023161326A1 (en) 2022-02-24 2023-08-31 Galapagos Nv Compound for use in and methods of treatment of inflammatory diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2251341A1 (en) * 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
EP2809671B1 (en) * 2012-01-30 2016-01-13 Cephalon, Inc. Imidazo [4, 5 - b]pyridine derivatives as alk and jak modulators for the treatment of proliferative disorders
GB201401086D0 (en) * 2014-01-23 2014-03-12 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2017012647A1 (en) 2015-07-20 2017-01-26 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AR105400A1 (es) * 2015-08-04 2017-09-27 Lilly Co Eli Inhibidores de jak1
CN110300590A (zh) * 2016-10-21 2019-10-01 林伯士拉克许米公司 Tyk2抑制剂及其用途
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
EP3697784B9 (en) 2023-12-27
IL273943B1 (en) 2023-06-01
US20210169879A1 (en) 2021-06-10
EP3697784B1 (en) 2023-10-04
US11564923B2 (en) 2023-01-31
PH12020550230A1 (en) 2021-02-08
JP2020537672A (ja) 2020-12-24
AU2018350592B2 (en) 2022-12-22
AU2023201522A1 (en) 2023-04-13
AR113784A1 (es) 2020-06-10
US20230310433A1 (en) 2023-10-05
KR20200074178A (ko) 2020-06-24
CA3079449A1 (en) 2019-04-25
RU2020116376A3 (hu) 2021-11-22
EP4265254A2 (en) 2023-10-25
CN111225916A (zh) 2020-06-02
IL273943B2 (en) 2023-10-01
CN111225916B (zh) 2023-11-03
JP7292271B2 (ja) 2023-06-16
RU2020116376A (ru) 2021-11-22
ES2967432T3 (es) 2024-04-30
AU2018350592A1 (en) 2020-06-04
DK3697784T3 (da) 2023-10-30
MA50391A (fr) 2021-04-21
RS64800B1 (sr) 2023-11-30
FI3697784T5 (fi) 2024-01-12
CO2020005200A2 (es) 2020-05-29
LT3697784T (lt) 2023-10-25
SG11202003516TA (en) 2020-05-28
PL3697784T3 (pl) 2024-03-11
PT3697784T (pt) 2024-01-09
EP4265254A3 (en) 2024-03-13
BR112020007541A2 (pt) 2020-09-24
IL302615A (en) 2023-07-01
WO2019076716A1 (en) 2019-04-25
HRP20231315T1 (hr) 2024-02-16
JP2023113834A (ja) 2023-08-16
CN117534670A (zh) 2024-02-09
TW201918483A (zh) 2019-05-16
SI3697784T1 (sl) 2023-11-30
MX2020003863A (es) 2020-08-13
EP3697784A1 (en) 2020-08-26
MA50391B1 (fr) 2023-11-30
FI3697784T3 (fi) 2023-10-31
TWI805629B (zh) 2023-06-21
ZA202002166B (en) 2021-05-26
IL273943A (en) 2020-05-31
GB201717260D0 (en) 2017-12-06
DK3697784T5 (da) 2024-01-15

Similar Documents

Publication Publication Date Title
FI3697784T5 (fi) Imidatso[4,5-b]pyridiiniyhdisteet ja niiden farmaseuttiset koostu- mukset tulehduksellisten häiriöiden hoitoa varten
PL3838274T3 (pl) Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
IL255109A0 (en) New dihydropyridoisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
SG11201907095UA (en) DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
GEP20207172B (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
EP3445352A4 (en) COMPOSITIONS FOR THE TREATMENT OF HYPERKERATOSIS RELATED DISORDERS
HK1247203A1 (zh) 取代的咪唑並[1,2-α]吡啶-2-基胺化合物及其藥物組合物和使用方法
EP3452455A4 (en) SUBSTITUTED IMDAZO [1,2-] PYRIDINES, SUBSTITUTED IMIDAZO [1,2-] PYRAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF ILLNESSES
EP3380471B8 (en) Tetrahydro-8h-pyrido[1,2-a]pyrazine-8-ones as comt inhibitors for the treatment of neurodegenerative disorders
HRP20181332T1 (hr) Derivati benzimidazola i njihovi farmaceutski pripravci, namijenjeni liječenju upalnih poremećaja
PL3500571T3 (pl) Związki imidazo[1,2-a]pirydynowe, kompozycje je zawierające, sposoby leczenia chorób z ich wykorzystaniem oraz sposoby ich wytwarzania
GB201610056D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
GB201610055D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
GB201702603D0 (en) Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
IL243739A0 (en) History of 1h-pyrazolo[4,3-b]pyridine and their pharmaceutical preparations for the treatment of proliferative disorders
WO2016083315A8 (en) Use of ox1r antagonists for the treatment of inflammatory bowel diseases
GB201702604D0 (en) Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3261630A4 (en) Compositions and combinations for the treatment of angiogenesis diseases and disorders